MX2023005675A - Agentes farmacológicos para tratar afecciones del ojo. - Google Patents

Agentes farmacológicos para tratar afecciones del ojo.

Info

Publication number
MX2023005675A
MX2023005675A MX2023005675A MX2023005675A MX2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A MX 2023005675 A MX2023005675 A MX 2023005675A
Authority
MX
Mexico
Prior art keywords
eye
pharmacological agents
treating conditions
reducing
treating
Prior art date
Application number
MX2023005675A
Other languages
English (en)
Spanish (es)
Inventor
Santosh C Sinha
Sridhar Govinda Prasad
Marshall C Peterman
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of MX2023005675A publication Critical patent/MX2023005675A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023005675A 2020-11-13 2021-11-15 Agentes farmacológicos para tratar afecciones del ojo. MX2023005675A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113691P 2020-11-13 2020-11-13
US202163215818P 2021-06-28 2021-06-28
PCT/US2021/072405 WO2022104383A1 (en) 2020-11-13 2021-11-15 Pharmacological agents for treating conditions of the eye

Publications (1)

Publication Number Publication Date
MX2023005675A true MX2023005675A (es) 2023-07-31

Family

ID=81601792

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005675A MX2023005675A (es) 2020-11-13 2021-11-15 Agentes farmacológicos para tratar afecciones del ojo.

Country Status (6)

Country Link
US (1) US20240000812A1 (enExample)
EP (1) EP4243798A4 (enExample)
JP (1) JP2023549533A (enExample)
CA (1) CA3202073A1 (enExample)
MX (1) MX2023005675A (enExample)
WO (1) WO2022104383A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2025090994A1 (en) * 2023-10-26 2025-05-01 Plex Pharmaceuticals, Inc. Compositions for treating cataracts and/or presbyopia eye diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439863T1 (de) * 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
JP6068484B2 (ja) * 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダSom Innovation Biotech, S.L. トランスサイレチン関連アミロイドーシスの新規療法
WO2013098416A2 (fr) * 2011-12-30 2013-07-04 Ecole Nationale Superieure De Chimie De Clermont Ferrand Composes anti-douleur
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
US20160317474A1 (en) * 2013-12-18 2016-11-03 Emory University Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
EP3683618A1 (en) * 2019-01-21 2020-07-22 Essilor International (Compagnie Generale D'optique) System and method for demonstrating an optical disorder
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
JP2024520837A (ja) * 2021-06-08 2024-05-24 プレックビジョン、バイオテクノロジーズ、リミテッド ダニの抑制又は滅殺及び眼球乾燥症の治療におけるcyp450阻害剤の使用

Also Published As

Publication number Publication date
EP4243798A1 (en) 2023-09-20
WO2022104383A1 (en) 2022-05-19
JP2023549533A (ja) 2023-11-27
CA3202073A1 (en) 2022-05-19
US20240000812A1 (en) 2024-01-04
EP4243798A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
Bullimore et al. The risks and benefits of myopia control
Shunmugam et al. Giant retinal tears
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2024015479A (es) Moduladores de la via de respuesta integrada al estres
PH12023550153A1 (en) Inhibitors of complement factors and uses thereof
CR20210395A (es) Moduladores de la expresión de hsd17b13
UY30061A1 (es) Inhibición de hif 1a mediada por arni para el tratamiento de la angiogénesis ocular
MX2024001713A (es) Metodos y composiciones para tratar la apnea del sue?o.
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
PH12020551995A1 (en) Modulator of apol1 expression
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
WO2019140372A3 (en) Methods of treatment by inhibition of bfl 1
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
WO2007011875A3 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
MX2022009025A (es) Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
RU2010116859A (ru) ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА В ЛЕЧЕНИИ РАССЕЯННОГО СКЛЕРОЗА И АУТОИММУННОГО МИЕЛИТА
Wang et al. Comparative study of femtosecond laser‐assisted cataract surgery and conventional phacoemulsification in vitrectomized eyes
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2023013504A (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1).
MX2025013710A (es) Composiciones para mejorar el sueño y métodos de uso
MX2021014682A (es) Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
MX2022013927A (es) Composiciones y metodos para tratar la epilepsia.